A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance

Trial Profile

A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Pazopanib (Primary) ; Paclitaxel
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms TAPAZ
  • Most Recent Events

    • 21 Oct 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 16 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top